New formulations and alternative injection sites might allow self-administration of long-acting cabotegravir and rilpivirine
Adolescents and women who experience violence more likely to get HIV and less likely to control it
Biktarvy combination pill may be most effective option for people with HIV and hepatitis B
Weight gain on treatment: more evidence that TAF plus dolutegravir leads to greater gains
Better PrEP retention strategies are needed, as increasing numbers of ex-PrEP users are diagnosed with HIV
HIV treatment adherence may be another casualty of climate change
How PEPFAR countries sustained HIV programmes in 2020 amidst COVID-19
Substantial weight gain as dolutegravir is rolled out in Africa
Integrase inhibitors raise the risk of heart attack, stroke during first two years of treatment
